Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 378

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial

Ohman, E. Magnus, Kleiman, Neal S., Gacioch, Gerald, Worley, Seth J., Navetta, Frank I., Talley, J. David, Anderson, H. Vernon, Ellis, Stephen G., Cohen, Mark D., Spriggs, Douglas, Miller, Michael, Kereiakes, Dean, Yakubov, Steven, Kitt, Michael M., Sigmon, Kristina N., Califf, Robert M., Krucoff, Mitchell W., Topol, Eric J.·1997·Circulation

Abstract

Background Platelet activation and aggregation may be key components of thrombolytic failure to restore and maintain perfusion in acute myocardial infarction. We performed a placebo-controlled, dose-ranging trial of Integrilin, a potent inhibitor of platelet aggregation, with heparin, aspirin, and accelerated alteplase. Methods and Results We assigned 132 patients in a 2:1 ratio to receive a bolus and continuous infusion of one of six Integrilin doses or placebo. Another 48 patients were randomized in a 3:1, double-blind fashion to receive the highest Integrilin dose from the first phase or placebo. All patients received accelerated alteplase, aspirin, and intravenous heparin infusion; all but two groups also received an intravenous heparin bolus. The highest Integrilin dose group from the nonrandomized phase and the randomized patients were pooled for analysis and compared with placebo-treated patients. The primary end point was Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow at 90-minute angiography. Secondary end points were time to ST-segment recovery, an in-hospital composite (death, reinfarction, stroke, revascularization procedures, new heart failure, or pulmonary edema), and bleeding variables. The highest Integrilin dose groups had more complete reperfusion (TIMI grade 3 flow, 66% versus 39% for placebo-treated patients; P =.006) and a shorter median time to ST-segment recovery (65 versus 116 minutes for placebo; P =.05). The groups had similar rates of the composite end point (43% versus 42% for placebo-treated patients) and severe bleeding (4% versus 5%, respectively). Conclusions The incidence and speed of reperfusion can be enhanced when a potent inhibitor of the glycoprotein IIb/IIIa integrin receptor, such as Integrilin, is combined with accelerated alteplase, aspirin, and intravenous heparin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.95.4.846

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 378

Metadata

Authors
Ohman, E. M., Kleiman, N. S., Gacioch, G., Worley, S. J., Navetta, F. I., Talley, J. D., Anderson, H. V., Ellis, S. G., Cohen, M. D., Spriggs, D., Miller, M., Kereiakes, D., Yakubov, S., Kitt, M. M., Sigmon, K. N., Califf, R. M., Krucoff, M. W., & Topol, E. J.
Venue
Circulation
Published
1997-02-18
Volume
95
Issue
4
Pages
846-854
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2094687142
Cited by
378
References
18
FWCI
40.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial. https://app.cochat.ai/papers/10.1161/01.cir.95.4.846
The paper
Ohman, E. M., Kleiman, N. S., Gacioch, G., Worley, S. J., Navetta, F. I., Talley, J. D., Anderson, H. V., Ellis, S. G., Cohen, M. D., Spriggs, D., Miller, M., Kereiakes, D., Yakubov, S., Kitt, M. M., Sigmon, K. N., Califf, R. M., Krucoff, M. W., & Topol, E. J. (1997). Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa Integrin Receptor Blockade With Integrilin in Acute Myocardial Infarction: Results of a Randomized, Placebo-Controlled, Dose-Ranging Trial. Circulation. https://doi.org/10.1161/01.cir.95.4.846

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.